My SciELO
Custom servicesServices on Demand
Journal
Article
English (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Cited by Google 
Similars in
SciELO 
Similars in Google
Share
Permalink
Ars Pharmaceutica (Internet)
On-line version ISSN 2340-9894
Abstract
CARRERA-HUESO, Francisco Javier et al. Use of Tocilizumab in hospitalized patients during the first wave of the COVID-19 pandemic. Ars Pharm [online]. 2022, vol.63, n.2, pp.166-172. Epub Apr 25, 2022. ISSN 2340-9894. https://dx.doi.org/10.30827/ars.v63i2.22348.
Introduction:
The aim of this study was to characterize the use of tocilizumab in a hospital.
Method:
Retrospective cohort study including adult SARS-CoV-2 infected inpatients with moderately severe infection (PaO2/FiO2 < 300). ORs for mortality and treatment success were calculated.
Results:
The tocilizumab group (n=18), presented 5 days of symptoms vs 7 days in the untreated group (n=71). Minimum PaO2/FiO2 was 147.5 (95%CI: 116.7 to 194.0) vs 255.6 (95%CI: 320.7 to 452.4) (p=0.01).
No significant differences were found between the two groups concerning survival (OR=1.22; 95%CI: 0.38 to 3.92), nor treatment success (OR=0.46; 95%CI: 0.16 to 1.33). After adjusting for age, sex and total corticosteroid dose, OR for success was 0.18 (95%CI: 0.03 to 0.96), while mortality was not significant.
Conclusions:
The use of tocilizumab in moderately severe hospitalized patients could decrease the hyperinflammatory state preventing disease progression.
Keywords : Tocilizumab; COVID-19; cohort study.
